Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.

Abstract

Zytiga (abiraterone acetate, AA) is known to exhibit very low bioavailability and a significant positive food effect in men. The unfavorable pharmacokinetic properties are attributed to the inadequate and variable dissolution of the compound. Using a continuous flow precipitation technology, a novel AA formulation has been developed with improved solubility and dissolution characteristics. The current study was performed to evaluate the pharmacokinetics and safety of this novel formulation in healthy volunteers. The study was conducted in 11 healthy men aged 47-57years. All subjects received 3 consecutive single doses of the novel formulation of AA (100 and 200mg in the fasted state and 200mg in the fed state). Data were compared with pharmacokinetic and safety data reported for 1000mg Zytiga, the marketed drug. The novel formulation of AA allows rapid absorption of the compound with t max values within 1hour. Based on AUC values, a ~250mg dose of the novel formulation is predicted to give the same exposure as 1000mg Zytiga in the fasted state. The significant positive food effect was also eliminated; actually, a slight, but statistically significant negative food effect was observed. Variability of exposure was significantly reduced when compared to Zytiga. AA administered in the novel formulation was well tolerated with no IMP-related safety AEs reported. The novel formulation might allow a 75% dose reduction with significant reduction of inter-individual variability. The negative food effect observed requires further investigations; however, elimination of the significant positive food effect could be adequate to negate the restriction of a food label.